Literature DB >> 561650

Lymphangiography in patients with ovarian epithelial cancer: an evaluation of 289 consecutive cases.

R Musumeci, A Banfi, G Bolis, G B Candiani, G De Palo, F Di Re, L Lucina, A Lattuada, C Mangioni, G Mattioli, N Natale.   

Abstract

From January, 1973, to June, 1976, 226 patients with palpable ovarian masses were evaluated preoperatively by lymphography. Histology showed 166 cases of malignant epithelial tumors, 26 benign tumors, and 34 malignant special tumors (not included in this report). Furthermore, the group of patients included 99 recurrences of ovarian epithelial cancer and 24 patients who underwent restaging diagnostic procedures without clinical evidence of disease. Lymphography was negative in all patients with benign tumors. In the 289 cases of epithelial cancer, lymphangiography gave evidence of nodal metastases in 88 (30%). When the histological subtype was considered, the highest incidence of metastases was in undifferentiated carcinoma (50%) and the lowest, in mesonephroid carcinoma (14%). According to the stage before lymphography, nodal metastases were found in 8% of Stage I, 0% of Stage II, 29% of Stage III, and 53% of Stage IV cases. The incidence of metastases was 46% in patients studied for recurrent disease and 17% in patients studied for restaging. Fifty-four percent of patients had metastases only in the pelvic nodes and 18% only in the para-aortic chains; in 28% both chains were involved simultaneously. Bilateral involvement was found in 63% of the positive cases. Retroperitoneal node biopsies were performed in 68 patients (36%). The radiologic/histologic correlation was 100% in the lymphangiographically positive cases; 81% in the negative cases, with nine false-negative reports; and 87% in all cases.

Entities:  

Mesh:

Year:  1977        PMID: 561650     DOI: 10.1002/1097-0142(197710)40:4<1444::aid-cncr2820400414>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

Review 1.  Radiologic imaging modalities, including magnetic resonance, for evaluating lymph nodes.

Authors:  G C Dooms; H Hricak
Journal:  West J Med       Date:  1986-01

2.  The lymphatic drainage of the human ovary in vivo investigated by isotopic lymphography before and after the menopause.

Authors:  G Vanneuville; D Mestas; G Le Bouedec; A Veyre; J Dauplat; G Escande; M Guillot
Journal:  Surg Radiol Anat       Date:  1991       Impact factor: 1.246

3.  Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer. A randomized clinical study.

Authors:  G Bolis; G Bortolozzi; G Carinelli; M D'Incalci; F Gramellini; L Morasca; C Mangioni
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

4.  Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis.

Authors:  A Maggioni; P Benedetti Panici; T Dell'Anna; F Landoni; A Lissoni; A Pellegrino; R S Rossi; S Chiari; E Campagnutta; S Greggi; R Angioli; N Manci; M Calcagno; G Scambia; R Fossati; I Floriani; V Torri; R Grassi; C Mangioni
Journal:  Br J Cancer       Date:  2006-08-29       Impact factor: 7.640

Review 5.  Ovarian cancer initially presenting with isolated ipsilateral superficial inguinal lymph node metastasis: a case study and review of the literature.

Authors:  Xiao-Jun Yang; Fei-Yun Zheng; Yun-Sheng Xu; Rong-Ying Ou
Journal:  J Ovarian Res       Date:  2014-02-10       Impact factor: 4.234

6.  Clinical outcome and prognostic factors of patients with early-stage epithelial ovarian cancer.

Authors:  Wei Wei; Ning Li; Yangchun Sun; Bin Li; Lily Xu; Lingying Wu
Journal:  Oncotarget       Date:  2017-04-04

7.  Left inguinal adenopathy two years after cytoreductive surgery: a rare sign of recurrence.

Authors:  Aibek E Mirrakhimov; Nwabundo Nwankwo; Aram Barbaryan; Raya Saba; Alaa M Ali; Shawn G Kwatra; Nasir Hussain; Mourad H Senussi; Erwin Velasquez Kho; Alan D Gilman
Journal:  Case Rep Oncol       Date:  2013-01-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.